DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sapacitabine
Sapacitabine
Research in Your Backyard Developing Cures, Creating Jobs
Chemotherapeutic Treatment of Acute Myeloid Leukemia
Draft COMP Agenda 16-18 January 2018
WO 2010/135468 Al
20 13 Rep Or T
Leukemia I N S I G H T S VOL
A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure 2013-0870
WHO Drug Information Vol. 20, No. 3, 2006
Apacita Bine
Hematology Drugs in the Pipeline
A Randomised Comparison of the Novel Nucleoside Analogue Sapacitabine with Low-Dose Cytarabine in Older Patients with Acute Myeloid Leukaemia
Translational Oncology: How to Better Transform Targets Into Relevant Drugs for Patients
Less Intensive 1 (LI1) Trial: a Randomized Phase
Translating Cancer Biology Into Medicines
Orphan Drug Dummy File
HDAC Inhibition Induces Microrna-182, Which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myel
Novel Drugs for Older Patients with Acute Myeloid Leukemia
Stembook 2018.Pdf
Top View
Leukemia Insights Newsletter November 2019
(12) Patent Application Publication (10) Pub. No.: US 2013/0196938 A1 GREEN Et Al
Supplementary Tables
Translating Cancer Biology Into Medicines
Recent Advances in the Management of Hematologic Malignancies
Sapacitabine Clinical Trials • • Sapacitabine Clinicalprogress Trials in • • • •
Deoxycytidine-Derivative, in Human Cancer Cells
Chronic Lymphocytic Leukemia: Evolution of in This Issue
FDA-Approved Drug Library Mini (96-Well)
Orphan Drug Designation List
Leukemia Insights Summer 2011
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: from Dose Puzzle to Pharmacogenomic Biomarkers
Q4 2019 Cyclacel Pharmaceuticals Inc Earnings Call on February 26
Draft COMP Agenda 6-8 November 2018
Leukemia Insights Spring 2011
Therapeutic Advances in Oncology
Wo 2010/095940 A2
Core Submission Dossier
A Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS)
Innovative Medicines for Cancer and Other Proliferative Diseases Using Cell Cycle Biology
Drugmakers Brush Off Failure and Keep Trying in AML
Cyclacel Pharmaceuticals, Inc
THERAPY CODES 4-Factor Concentrate F014 5A2A F017
WO 2016/123581 Al 4 August 2016 (04.08.2016) P O P C T
Precision Therapy for Acute Myeloid Leukemia Xue Yang and Jianxiang Wang*
TDP1 Is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside Also Targeting ATM- and BRCA-Deficient Tumors
Improvement of the Antitumor Activity of Poorly Soluble Sapacitabine
(12) Patent Application Publication (10) Pub. No.: US 2016/0221987 A1 Decrescenzo Et Al
Translating Cancer Biology Into Medicines
Hematology Drugs in the Pipeline
Sapacitabine for Patients with Acute Myeloid Leukaemia Who Are Not Eligible for Intensive Treatment – First Line
Oncology Drugs in the Pipeline
Leukemia Lymphoma Myeloma 5Th International Congress
And BRCA-Deficient Tumors
Potential for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Differences Between Intrinsic and Acquired Nucleoside Analogue
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Inhibition of P53 Inhibitors: Progress, Challenges and Perspectives
Ramesh Rengan, MD Ph.D. Radiation Therapy Contraindications And
Medicines & Vaccines in Development for Cancer
Mutations in Acute Myeloid Leukemia
A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide
Adis R&D Insight
( 12 ) United States Patent
Form 10-K Cyclacel Pharmaceuticals, Inc
United States Securities and Exchange Commission Form
WO 2016/025904 Al 18 February 2016 (18.02.2016) P O P C T
Leukemia-Myelodysplastic Syndrome and Transplantation
Targeting DNA Repair Pathways in Hematological Malignancies
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016